New combo therapy shows promise for rare liposarcoma
NCT ID NCT04794127
First seen Feb 22, 2026 · Last updated May 23, 2026 · Updated 13 times
Summary
This study tested whether adding pioglitazone (a diabetes drug) to trabectedin (a chemotherapy) can help shrink or control liposarcoma, a rare cancer of fat tissue. It included 10 adults whose cancer had stopped growing but not shrunk after at least 4 cycles of trabectedin alone. The goal was to see if the combination could trigger tumor shrinkage or improve disease control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIPOSARCOMA, DEDIFFERENTIATED are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fondazione IRCCS Istituto Nazionale Tumori
Milan, MI, 20133, Italy
Conditions
Explore the condition pages connected to this study.